montelukast ratiopharm (montelukast teva) filmuhúðuð tafla 10 mg
teva sweden ab - montelukastum natríum - filmuhúðuð tafla - 10 mg
singulair filmuhúðuð tafla 10 mg
n.v. organon* - montelukastum natríum - filmuhúðuð tafla - 10 mg
montelukast ratiopharm (montelukast teva) tuggutafla 4 mg
teva sweden ab - montelukastum natríum - tuggutafla - 4 mg
montelukast ratiopharm (montelukast teva) tuggutafla 5 mg
teva sweden ab - montelukastum natríum - tuggutafla - 5 mg
singulair tuggutafla 4 mg
n.v. organon* - montelukastum natríum - tuggutafla - 4 mg
pentocur (tiopental abcur) stungulyfsstofn, lausn 1 g
abcur ab - thiopentalum natricum inn - stungulyfsstofn, lausn - 1 g
fluticasone alvogen (nasofan) nefúði, dreifa 50 míkróg/skammt
alvogen ehf. - fluticasonum própíónat - nefúði, dreifa - 50 míkróg/skammt
clynav
elanco gmbh - puk-spdv-poly2#1 dna plasmíð erfðaskrá fyrir lax brisi sjúkdómur veira prótín - Ónæmislyf til atlantic lax, - atlantic lax - fyrir virka bólusetningar á atlantic lax til að draga úr skert daglega þyngdaraukningu, og draga úr jörðu og hjarta, brisi og vöðvum sár af völdum brisi sjúkdómur eftir sýkingu með laxfiska alphavirus undirgerð 3 (sav3).
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
arexvy
glaxosmithkline biologicals s.a. - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.